{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:57:19Z","timestamp":1792270639697,"version":"4.4.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Neurology and Neurosurgery"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.clineuro.2022.107572","type":"journal-article","created":{"date-parts":[[2022,12,26]],"date-time":"2022-12-26T11:17:51Z","timestamp":1672053471000},"page":"107572","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Molecular characteristics and prognostic factors of leptomeningeal metastasis in non-small cell lung cancer"],"prefix":"10.1016","volume":"225","author":[{"given":"Xiaocui","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangrui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chufan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panpan","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengjun","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clineuro.2022.107572_bib1","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1097\/JTO.0000000000000669","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitors for non-small-cell lung cancer patients with leptomeningeal carcinomatosis","volume":"10","author":"Liao","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.clineuro.2022.107572_bib2","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s11864-020-00759-3","article-title":"Leptomeningeal metastases in non-small cell lung cancer: optimal systemic management in NSCLC with and without driver mutations","volume":"21","author":"Alexander","year":"2020","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.clineuro.2022.107572_bib3","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/j.jtho.2016.06.029","article-title":"Leptomeningeal metastases in patients with NSCLC with EGFR mutations","volume":"11","author":"Li","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.clineuro.2022.107572_bib4","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2147\/CMAR.S347323","article-title":"Systematic immunological level determined the prognosis of leptomeningeal metastasis in lung cancer","volume":"14","author":"Hong","year":"2022","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.clineuro.2022.107572_bib5","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.lungcan.2015.05.023","article-title":"Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: a retrospective cohort analysis","volume":"89","author":"Kuiper","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.clineuro.2022.107572_bib6","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/JTO.0b013e3182398e4f","article-title":"Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy","volume":"7","author":"Morris","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.clineuro.2022.107572_bib7","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1093\/neuonc\/noq076","article-title":"EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer","volume":"12","author":"Eichler","year":"2010","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.clineuro.2022.107572_bib8","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.4103\/ijc.IJC_74_19","article-title":"Management of leptomeningeal metastases in non-small cell lung cancer","volume":"56","author":"Patil","year":"2019","journal-title":"Indian J. Cancer"},{"key":"10.1016\/j.clineuro.2022.107572_bib9","doi-asserted-by":"crossref","first-page":"937","DOI":"10.21037\/atm-21-1249","article-title":"Osimertinib for the treatment of epidermal growth factor receptor-mutated non-small cell lung cancer patients with leptomeningeal metastases and different T790M status","volume":"9","author":"Xu","year":"2021","journal-title":"Ann. Transl. Med"},{"key":"10.1016\/j.clineuro.2022.107572_bib10","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.3892\/ol.2016.4783","article-title":"Intrathecal chemotherapy as a treatment for leptomeningeal metastasis of non-small cell lung cancer: a pooled analysis","volume":"12","author":"Wu","year":"2016","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.clineuro.2022.107572_bib11","first-page":"112","article-title":"Clinical trials on intrathecal pemetrexed treated leptomeningeal metastases from solid tumors","volume":"44","author":"Pan","year":"2022","journal-title":"Chin. J. Oncol."},{"key":"10.1016\/j.clineuro.2022.107572_bib12","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/j.jtho.2021.06.017","article-title":"Liquid biopsy for advanced NSCLC: a consensus statement from the International Association for the study of lung cancer","volume":"16","author":"Rolfo","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.clineuro.2022.107572_bib13","article-title":"Cerebrospinal fluid cell-free DNA-Based detection of high level of genomic instability is associated with poor prognosis in NSCLC patients with leptomeningeal metastases","volume":"12","author":"Wu","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.clineuro.2022.107572_bib14","first-page":"v86","article-title":"Advances in the diagnosis, evaluation, and management of leptomeningeal disease","volume":"3","author":"Sener","year":"2021","journal-title":"Neurooncol. Adv."},{"key":"10.1016\/j.clineuro.2022.107572_bib15","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/neuonc\/noz024","article-title":"The RANO Leptomeningeal Metastasis Group proposal to assess response to treatment: lack of feasibility and clinical utility and a revised proposal","volume":"21","author":"Le Rhun","year":"2019","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.clineuro.2022.107572_bib16","first-page":"484","article-title":"Leptomeningeal metastases: a RANO proposal for response criteria","volume":"19","author":"Chamberlain","year":"2017","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.clineuro.2022.107572_bib17","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.clineuro.2022.107572_bib18","first-page":"1811","article-title":"Prognostic factors and clinical outcome of patients with lung adenocarcinoma with carcinomatous meningitis","volume":"32","author":"Nakamura","year":"2012","journal-title":"Anticancer Res."},{"key":"10.1016\/j.clineuro.2022.107572_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2018.11.022","article-title":"Leptomeningeal metastasis after effective first-generation EGFR TKI treatment of advanced non-small cell lung cancer","volume":"127","author":"Wu","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.clineuro.2022.107572_bib20","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1158\/2159-8290.CD-15-0369","article-title":"Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets","volume":"5","author":"Brastianos","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.clineuro.2022.107572_bib21","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/S1470-2045(17)30689-7","article-title":"Leptomeningeal metastases in non-small-cell lung cancer","volume":"19","author":"Cheng","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.clineuro.2022.107572_bib22","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1093\/neuonc\/noz208","article-title":"A retrospective, quantitative assessment of disease burden in patients with leptomeningeal metastases from non-small-cell lung cancer","volume":"22","author":"Nevel","year":"2020","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.clineuro.2022.107572_bib23","article-title":"Differentiation of leptomeningeal and vascular enhancement on post-contrast FLAIR MRI sequence: role in early detection of infectious meningitis","volume":"9","author":"Ahmad","year":"2015","journal-title":"J. Clin. Diagn. Res."},{"key":"10.1016\/j.clineuro.2022.107572_bib24","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.2169\/internalmedicine.54.4081","article-title":"Patchy cerebral meningitis: spatiotemporal resolution using contrast-enhanced FLAIR-MRI","volume":"54","author":"Mishima","year":"2015","journal-title":"Intern. Med."},{"key":"10.1016\/j.clineuro.2022.107572_bib25","first-page":"193","article-title":"Diagnosis and treatment consensus of brain and leptomeningeal metastasis from lung cancer","volume":"18","author":"Long","year":"2018","journal-title":"J. Evid. -Based Med."},{"key":"10.1016\/j.clineuro.2022.107572_bib26","first-page":"71","article-title":"Shanghai expert consensus on the management of brain metastasis of non-small cell lung cancer with driver gene mutations","volume":"29","author":"Xiaohua","year":"2019","journal-title":"China Oncol."},{"key":"10.1016\/j.clineuro.2022.107572_bib27","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S2213-2600(18)30264-9","article-title":"Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial","volume":"6","author":"Wang","year":"2018","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.clineuro.2022.107572_bib28","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1200\/EDBK_237863","article-title":"Biomarker testing for patients with advanced non-small cell lung cancer: real-world issues and tough choices","volume":"39","author":"Pennell","year":"2019","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.clineuro.2022.107572_bib29","doi-asserted-by":"crossref","first-page":"8839","DOI":"10.1038\/ncomms9839","article-title":"Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma","volume":"6","author":"De Mattos-Arruda","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.clineuro.2022.107572_bib30","doi-asserted-by":"crossref","first-page":"7048","DOI":"10.21037\/jtd.2020.04.20","article-title":"Liquid biopsy is a valuable tool in the diagnosis and management of lung cancer","volume":"12","author":"Cecchini","year":"2020","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.clineuro.2022.107572_bib31","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/1759-7714.13300","article-title":"Detection of circulating tumor DNA from non-small cell lung cancer brain metastasis in cerebrospinal fluid samples","volume":"11","author":"Ma","year":"2020","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.clineuro.2022.107572_bib32","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12943-022-01543-7","article-title":"Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments","volume":"21","author":"Lone","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.clineuro.2022.107572_bib33","doi-asserted-by":"crossref","first-page":"i10","DOI":"10.1093\/annonc\/mdx703","article-title":"Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors","volume":"29","author":"Westover","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.clineuro.2022.107572_bib34","doi-asserted-by":"crossref","first-page":"543","DOI":"10.21147\/j.issn.1000-9604.2017.06.09","article-title":"Uncommon EGFR mutations in a cohort of Chinese NSCLC patients and outcomes of first-line EGFR-TKIs and platinum-based chemotherapy","volume":"29","author":"Shi","year":"2017","journal-title":"Chin. J. Cancer Res."},{"key":"10.1016\/j.clineuro.2022.107572_bib35","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/nm.3854","article-title":"Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M","volume":"21","author":"Thress","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.clineuro.2022.107572_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2019.102820","article-title":"Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: review of the literature and future perspectives","volume":"146","author":"Rebuzzi","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.clineuro.2022.107572_bib37","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.clineuro.2022.107572_bib38","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1200\/JCO.2018.77.9363","article-title":"CNS efficacy of osimertinib in patients with T790M-Positive advanced non-small-cell lung cancer: data from a randomized phase III trial (AURA3)","volume":"36","author":"Wu","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.clineuro.2022.107572_bib39","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1158\/1535-7163.MCT-16-0522","article-title":"MET copy number gain is associated with gefitinib resistance in leptomeningeal carcinomatosis of EGFR-mutant lung cancer","volume":"16","author":"Nanjo","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.clineuro.2022.107572_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.2019.37.15_suppl.9028","article-title":"Tissue-based molecular and histological landscape of acquired resistance to osimertinib given initially or at relapse in patients with EGFR-mutant lung cancers","volume":"37","author":"Schoenfeld","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.clineuro.2022.107572_bib41","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/s41571-020-0377-z","article-title":"MET-dependent solid tumours - molecular diagnosis and targeted therapy","volume":"17","author":"Guo","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.clineuro.2022.107572_bib42","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4103\/ijc.IJC_455_19","article-title":"Management of CNS metastases in patients with EGFR mutation-positive NSCLC","volume":"56","author":"Shetty","year":"2019","journal-title":"Indian J. Cancer"},{"key":"10.1016\/j.clineuro.2022.107572_bib43","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.78.3118","article-title":"CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-Mutated advanced non-small-cell lung cancer","author":"Reungwetwattana","year":"2018","journal-title":"J. Clin. Oncol:Jco"},{"key":"10.1016\/j.clineuro.2022.107572_bib44","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2018-CT013","article-title":"Abstract CT013: osimertinib displays high brain exposure in healthy subjects with intact blood-brain barrier: a microdose positron emission tomography (PET) study with 11C-labelled osimertinib","volume":"78","author":"Vishwanathan","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.clineuro.2022.107572_bib45","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.9005","article-title":"CNS response to osimertinib in patients (pts) with T790M-positive advanced NSCLC: data from a randomized phase III trial (AURA3)","volume":"35","author":"Mok","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.clineuro.2022.107572_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2020.116706","article-title":"Leptomeningeal metastasis from solid tumors","volume":"411","author":"Thakkar","year":"2020","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.clineuro.2022.107572_bib47","first-page":"399","article-title":"Survival analysis of different kinds of tyrosine kinase inhibitors in the treatment of patients with epidermal growth factor receptor mutated non-small cell lung cancer and leptomeningeal metastasis","volume":"102","author":"Haiyan","year":"2022","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.clineuro.2022.107572_bib48","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jtho.2020.10.006","article-title":"Dual EGFR-VEGF pathway inhibition: a promising strategy for patients With EGFR-Mutant NSCLC","volume":"16","author":"Le","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.clineuro.2022.107572_bib49","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ejca.2019.08.021","article-title":"EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in patients with EGFR-mutant NSCLC and multiple brain metastases","volume":"121","author":"Jiang","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.clineuro.2022.107572_bib50","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s13691-019-00358-6","article-title":"Erlotinib and bevacizumab combination therapy for afatinib-refractory leptomeningeal carcinomatosis from EGFR-mutated lung cancer","volume":"8","author":"Abe","year":"2019","journal-title":"Int Cancer Conf. J."},{"key":"10.1016\/j.clineuro.2022.107572_bib51","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1093\/annonc\/mds590","article-title":"Systematic review and meta-analysis of randomised, phase II\/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer","volume":"24","author":"Soria","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.clineuro.2022.107572_bib52","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3390\/curroncol29010004","article-title":"New strategies and combinations to improve outcomes in immunotherapy in metastatic non-small-cell lung cancer","volume":"29","author":"Corke","year":"2021","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.clineuro.2022.107572_bib53","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.lungcan.2017.02.022","article-title":"Symptomatic leptomeningeal metastasis improvement with nivolumab in advanced non-small cell lung cancer patient","volume":"108","author":"Gion","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.clineuro.2022.107572_bib54","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ejca.2019.05.019","article-title":"Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors","volume":"116","author":"Hendriks","year":"2019","journal-title":"Eur. J. Cancer"}],"container-title":["Clinical Neurology and Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030384672200453X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030384672200453X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T14:42:37Z","timestamp":1759588957000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030384672200453X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":54,"alternative-id":["S030384672200453X"],"URL":"https:\/\/doi.org\/10.1016\/j.clineuro.2022.107572","relation":{},"ISSN":["0303-8467"],"issn-type":[{"value":"0303-8467","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular characteristics and prognostic factors of leptomeningeal metastasis in non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Neurology and Neurosurgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clineuro.2022.107572","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107572"}}